How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

14,544 results for

Systemic Lupus Erythematosus

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

141. Familial aggregation of childhood and adulthood-onset Systemic Lupus Erythematosus. (Abstract)

Familial aggregation of childhood and adulthood-onset Systemic Lupus Erythematosus. To assess the familial occurrence of systemic lupus erythematosus (SLE) in a large Brazilian cohort.Consecutive SLE patients were recruited, and stratified according to age at disease-onset into childhood (cSLE) or adult (aSLE). Each patient was personally interviewed regarding history of SLE across three generations (first-, second-, and third-degree relatives). Recurrence rates were analyzed for each degree

2019 Arthritis care & research

142. Low Disease Activity State/Remission Predicts a Better Health-Related Quality of Life in Systemic Lupus Erythematosus Patients. (Abstract)

Low Disease Activity State/Remission Predicts a Better Health-Related Quality of Life in Systemic Lupus Erythematosus Patients. To determine if low disease activity state (LDAS)/Remission predicts a better health-related quality of life (HRQoL).Systemic lupus erythematosus (SLE) patients from a single center with at least two visits were included. Visits were performed every six months. HRQoL was measured with the LupusQoL. Remission: a SLEDAI-2K=0, prednisone daily dose≤5mg/d

2019 Arthritis care & research

143. Relationships Between Adverse Childhood Experiences and Health Status in Systemic Lupus Erythematosus. (Abstract)

Relationships Between Adverse Childhood Experiences and Health Status in Systemic Lupus Erythematosus. Adverse childhood experiences (ACEs) are associated with poor adult health and immune dysregulation. The impact of ACEs on patients with autoimmune disease is unknown. We compared the prevalence of ACEs in Systemic Lupus Erythematosus (SLE) patients to population-based survey estimate and investigated relationships between ACEs and SLE outcomes.Data derive from the California Lupus (...) Epidemiology Study (CLUES), a sample of adult SLE patients. Participants completed a 10-item ACE questionnaire covering 3 domains (abuse, neglect, household challenges). We estimated ACEs prevalence in 269 CLUES participants compared to 2015 California Behavioral Risk Factor Surveillance System (BRFSS) geographically matched respondents, standardized (age, sex, race/ethnicity) to CLUES participant characteristics. We examined associations for patient-reported and physician-assessed health status measures

2019 Arthritis care & research

144. An emerging role of neutrophils and NETosis in chronic inflammation and fibrosis in systemic lupus erythematosus (SLE) and ANCA-associated vasculitides (AAV): Implications for the pathogenesis and treatment. (Abstract)

An emerging role of neutrophils and NETosis in chronic inflammation and fibrosis in systemic lupus erythematosus (SLE) and ANCA-associated vasculitides (AAV): Implications for the pathogenesis and treatment. Neutrophils derive from hematopoietic stem cells (HSCs) with systemic inflammation driving their activation and differentiation to myeloid progenitors to ensure enhanced myelopoiesis. Epigenetic reprograming and re-education of these HSCs produces neutrophils primed towards elimination (...) may not be present in chronic inflammatory lesions, their remnants may amplify the inflammatory response beyond their short life-span in the tissues. Herein, we review current evidence supporting a role of neutrophils and NETosis in tissue injury and dysfunction in systemic autoimmunity using as disease paradigms Systemic Lupus Erythematosus (SLE) and the ANCA-associated vasculitides (AAV). We also discuss the mechanisms involved and their potential as targets for novel therapy and drug

2019 Autoimmunity reviews

145. New therapies for systemic lupus erythematosus - past imperfect, future tense. Full Text available with Trip Pro

New therapies for systemic lupus erythematosus - past imperfect, future tense. The failure of many new, mostly biologic, drugs to meet their primary end points in double-blind clinical trials in patients with systemic lupus erythematosus (SLE) has caused a profound sense of disappointment among both physicians and patients. Arguably, the success of B cell depletion with rituximab in open-label clinical trials, the approval of belimumab (which blocks B cell-activating factor (BAFF)) for use (...) in patients with lupus nephritis in the USA and in difficult-to-treat patients with SLE in the UK and the recognition that clinical trial design can be improved have given some cause for hope. However, changes to therapies in current use and the development of new approaches are urgently needed. The results of the latest studies investigating the use of several new approaches to treating SLE are discussed in this Review, including: fully humanized anti-CD20 and anti-CD19 monoclonal antibodies; inhibition

2019 Nature reviews. Rheumatology

146. A retrospective study of patients with systemic lupus erythematosus combined with Pneumocystis jiroveci pneumonia treated with caspofungin and trimethoprim/sulfamethoxazole. Full Text available with Trip Pro

A retrospective study of patients with systemic lupus erythematosus combined with Pneumocystis jiroveci pneumonia treated with caspofungin and trimethoprim/sulfamethoxazole. Systemic lupus erythematosus (SLE) complicated with Pneumocystis jiroveci pneumonia (PCP) is a clinical complex with unsatisfying treatment efficacy and poor prognosis which is difficult to be diagnosed at early stage. The present study aimed to investigate the clinical features of SLE with PCP, recognize the early onset

2019 Medicine

147. Lack of patient education is risk factor of disease flare in patients with systemic lupus erythematosus in China. Full Text available with Trip Pro

Lack of patient education is risk factor of disease flare in patients with systemic lupus erythematosus in China. To explore the inadequacies of health service and its impact on clinical outcomes of patients with systemic lupus erythematosus (SLE) in China.A total of 210 SLE patients were randomly recruited between January 2017 and January 2018. Each patient received self-report questionnaires to assess medication adherence [Compliance Questionnaire for Rheumatology (CQR)], beliefs about (...) with SIMS, EuroQol five-dimensions [EQ5D], Systemic Lupus International Collaborating Clinics (SLICC), depression, use of NSAID (P ≤ 0.05). Remission of disease was positively correlated with SIMS (OR = 0.16, 95% CI: [0.06, 0.40]), and BMQ (OR = 0.64, 95%CI: [0.43, 0.94]).In this study, the scores of BMQ and SIMS were low, implying defects in the patient education of health service system, which led to disease flare in Chinese SLE patients.ClinicalTrials.gov ID: NCT03024307 . Registered January 18, 2017.

2019 BMC health services research

148. Abnormal Cardiac Biomarkers in Patients with Systemic Lupus Erythematosus and No Prior Heart Disease: The Role of Endomyocardial Biopsy. Full Text available with Trip Pro

Abnormal Cardiac Biomarkers in Patients with Systemic Lupus Erythematosus and No Prior Heart Disease: The Role of Endomyocardial Biopsy. Tselios, et al reported in their recent study that patients with systemic lupus erythematosus (SLE) who receive prolonged antimalarial (AM) treatment are at increased risk for elevated cardiac biomarkers [brain natriuretic peptide (BNP) and high-sensitivity cardiac troponin I (HS-cTnI)], particularly when persistently elevated creatine phosphokinase (CPK

2019 Journal of Rheumatology

149. T cell receptor β repertoires as novel diagnostic markers for systemic lupus erythematosus and rheumatoid arthritis. (Abstract)

T cell receptor β repertoires as novel diagnostic markers for systemic lupus erythematosus and rheumatoid arthritis. T cell receptor (TCR) diversity determines the autoimmune responses in systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) and is closely associated with autoimmune diseases prognosis and prevention. However, the characteristics of variations in TCR diversity and their clinical significance is still unknown. Large series of patients must be studied in order

2019 Annals of the Rheumatic Diseases

150. Association of Epstein-Barr virus serological reactivation with transitioning to systemic lupus erythematosus in at-risk individuals. Full Text available with Trip Pro

Association of Epstein-Barr virus serological reactivation with transitioning to systemic lupus erythematosus in at-risk individuals. Systemic lupus erythematosus (SLE) is a systemic autoimmune disease with unknown aetiology. Epstein-Barr virus (EBV) is an environmental factor associated with SLE. EBV maintains latency in B cells with frequent reactivation measured by antibodies against viral capsid antigen (VCA) and early antigen (EA). In this study, we determined whether EBV reactivation

2019 Annals of the Rheumatic Diseases

151. Libman-Sacks Endocarditis Involving a Bioprosthesis in the Aortic Valve Position in Systemic Lupus Erythematosus. (Abstract)

Libman-Sacks Endocarditis Involving a Bioprosthesis in the Aortic Valve Position in Systemic Lupus Erythematosus. Described herein is a 39-year-old man with systemic lupus erythematosus not receiving corticosteroid therapy who developed Libman-Sacks endocarditis causing stenosis of a bioprosthesis in the aortic valve position.Copyright © 2019 Elsevier Inc. All rights reserved.

2019 American Journal of Cardiology

152. Development and Validation of a microRNA Panel to Differentiate between Patients with Rheumatoid Arthritis or Systemic Lupus Erythematosus and Controls. (Abstract)

Development and Validation of a microRNA Panel to Differentiate between Patients with Rheumatoid Arthritis or Systemic Lupus Erythematosus and Controls. MicroRNAs (miRNAs) are short non-coding RNAs that regulate genes and are both biomarkers and mediators of disease. We used small RNA (sRNA) sequencing and machine learning methodology to develop a miRNA panel to reliably differentiate between rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE) and control subjects.Plasma samples

2019 Journal of Rheumatology

153. Association of Childhood Abuse with Incident Systemic Lupus Erythematosus in Adulthood in a Longitudinal Cohort of Women. (Abstract)

Association of Childhood Abuse with Incident Systemic Lupus Erythematosus in Adulthood in a Longitudinal Cohort of Women. Exposure to severe stressors may alter immune function and augment inflammation and cytokine release, increasing autoimmune disease risk. We examined if childhood abuse was associated with heightened risk of incident systemic lupus erythematosus (SLE).Data were from the Nurses' Health Study II, a cohort of U.S. female nurses enrolled in 1989, followed with biennial

2019 Journal of Rheumatology

154. Blood Pressure Variability and Age-related Blood Pressure Patterns in Systemic Lupus Erythematosus. (Abstract)

Blood Pressure Variability and Age-related Blood Pressure Patterns in Systemic Lupus Erythematosus. Despite the high prevalence of cardiovascular disease among patients with systemic lupus erythematosus, the relationship between age, blood pressure, and blood pressure variability (BPV) is not well understood. We studied visit-to-visit BPV, its relationship to age, clinical, demographic characteristics and its potential role as a cardiovascular risk factor in patients with SLE.We analyzed (...) characteristics, and subsequent cardiovascular events.The mean systolic blood pressure (SBP) in SLE increased with age and was significantly higher in younger patients compared to the general population. BPV in systemic lupus was elevated across all age. BPV was significantly higher in African Americans, in patients with traditional cardiovascular risk factors, those with high disease activity, and in patients taking prednisone. Hydroxychloroquine was associated with significantly lower BPV. Within-person

2019 Journal of Rheumatology

155. Longitudinal disease- and steroid-related damage among adults with childhood-onset systemic lupus erythematosus. (Abstract)

Longitudinal disease- and steroid-related damage among adults with childhood-onset systemic lupus erythematosus. Determine whether adults with childhood-onset systemic lupus erythematosus (cSLE) are at increased risk for disease- and steroid-related damage as compared to individuals with adult-onset SLE (aSLE), and whether they continue to accumulate disease damage in adulthood.Data derive from the 2007-2015 cycles of the Lupus Outcomes Study, a longitudinal cohort of adults with confirmed SLE (...) . The Brief Index of Lupus Damage (BILD), a validated, patient-reported measure, was used to assess SLE-associated damage. Participants with baseline BILD were included (N = 1035). Diagnosis at age < 18 years was defined as cSLE (N = 113). Outcome variables included BILD score at baseline and follow-up, clinically significant change in BILD score over follow-up period, and presence of steroid-related damage (cataracts, osteoporosis-related fracture, avascular necrosis or diabetes mellitus).Mean time

2019 Seminars in arthritis and rheumatism

156. Can we validate a clinical score to predict the risk of severe infection in patients with systemic lupus erythematosus? A longitudinal retrospective study in a British Cohort. Full Text available with Trip Pro

Can we validate a clinical score to predict the risk of severe infection in patients with systemic lupus erythematosus? A longitudinal retrospective study in a British Cohort. Severe infections are a major cause of morbidity and mortality in patients with systemic lupus erythematosus (SLE). Our primary objective was to use data from a large Spanish cohort to develop a risk score for severe infection in SLE, the SLE Severe Infection Score (SLESIS) and to validate SLESIS in a separate cohort

2019 BMJ open

157. Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol. Full Text available with Trip Pro

Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol. Belimumab, an anti-B-lymphocyte-stimulator antibody, is approved for the treatment of active, autoantibody-positive systemic lupus erythematosus (SLE). Rituximab, a B cell-depleting anti-CD20 antibody, remains in the SLE treatment armamentarium despite failed (...) trials in lupus nephritis and extrarenal lupus. These biologics, which operate through complementary mechanisms, might result in an enhanced depletion of circulating and tissue-resident autoreactive B lymphocytes when administered together. Thus, belimumab and rituximab combination may be a highly effective treatment of SLE. This study aims to evaluate and compare the efficacy, safety and tolerability of subcutaneous (SC) belimumab and a single cycle of rituximab in patients with SLE with belimumab

2019 BMJ open Controlled trial quality: predicted high

158. Seborrheic area involvement in patients with systemic lupus erythematosus. (Abstract)

Seborrheic area involvement in patients with systemic lupus erythematosus. The most characteristic skin manifestation of systemic lupus erythematosus (LE) is malar rash characterized by an erythematous congestive sometimes secondarily squamous eruption over the cheeks and nasal bridge, that typically spares nasolabial folds. This rash is referred to as "acute cutaneous lupus erythematosus" (ACLE) (1). Recently, 2 SLE patients with remarkable skin involvement of seborrheic area (SA) came to our

2019 Journal of the European Academy of Dermatology and Venereology

159. Urinary podocyte microparticles are associated with disease activity and renal injury in systemic lupus erythematosus. Full Text available with Trip Pro

Urinary podocyte microparticles are associated with disease activity and renal injury in systemic lupus erythematosus. New non-invasive biomarkers are demanded to identify renal damage in various autoimmune-associated kidney diseases. Glomerular podocyte damage mediated by systemic lupus erythematosus (SLE) plays an important role in the pathogenesis and progression of lupus nephritis (LN). This study evaluated whether the podocyte-derived microparticles (MPs) were novel biomarkers of clinical

2019 BMC Nephrology

160. Risk of joint replacement surgery in Taiwanese female adults with systemic lupus erythematosus: a population-based cohort study. Full Text available with Trip Pro

Risk of joint replacement surgery in Taiwanese female adults with systemic lupus erythematosus: a population-based cohort study. Female patients with systemic lupus erythematosus (SLE) are prone to have musculoskeletal system involvement, which could lead to joint damage. However, few studies have assessed the incidence of arthroplasty in female patients with SLE. The aim of this study was to investigate the risk of total hip replacement surgery and total knee replacement surgery in patients

2019 BMC Musculoskeletal Disorders

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>